- About Us
- Business Development
- Contact Us
If you haven’t received the confirmation please check your junk mailbox.
You are already subscribed with the entered email address.
Your e-mail address is known to us, but you are inactive in the receipt list. We have sent you a confirmation email with an activation link to reactivate your account and receive the newsletter in the future.
You have signed up for the newsletter and receive a confirmation email on your entered email address containing an activation link that you must follow to confirm your application.
It may take a few minutes before you receive this email.
Together with Maastricht University and Lifeteczone, Basic Pharma organizes a symposium about the challenge in the development of biopharmaceuticals. REGISTER NOW!
|LOCATION:||Brightlands Chemelot Campus, Geleen (NL)|
A major challenge in the development of biopharmaceuticals is achieving clinical grade products for clinical evaluation. Under the framework of the Interreg V Netherlands and Flanders -project SkiN-HUID, Basic Pharma and MosaMedix, Universities of Maastricht, Antwerp and the Flemish Institute for Biotechnology (VIB) at the KU Leuven joined forces.
SKiN-HUID develops a novel treatment of skin cancer that combines administration of a biopharmaceutical medicine targeting cancer cells and application of electrical and hyperthermal stimulation of the cancer that enhances the efficacy of the biopharmaceutical medicine.
Within SKiN-HUID the consortium aims to overcome the major hurdle of bringing a novel biopharmaceutical product to the clinic: the GMP-production of clinical grade biopharmaceutical medicine for the first phase of clinical studies. Basic Pharma set up a novel pilot plant for the GMP-production of biopharmaceutical medicines. This facility forms an essential part of the value chain linking preclinical and clinical evaluation of the efficacy of biopharmaceutical medicines.
Collaboration between University and Industry is paramount in mastering this challenge. We cordially invite you to join our mission in accelerating personalised medicine innovations.
|13.10||Brightlands, a knowledge and technology hub to facilitate collaboration between Industry and University
Bert Kip, Brightlands Chemelot Campus
|13.20||SkiN-HUID, a euregional collaboration between Industry and Universities to improve the treatment of skin cancer.
Chris Reutelingsperger, Maastricht University
|13.35||Melanoma Patient-Derived Tumor Xenografts in mice as preclinical models to understand carcinogenesis and to predict efficacy of novel anticancer drugs
Michael Dewaele, VIB Center for Cancer Biology KULeuven
|13.55||The role of pathology in translating experimental treatments from the preclinic to clinical application.
Jean Paul Bogers, University of Antwerp
|14.20||GMP-production of biologicals for the first-in-man clinical study.
Ralph Bosmans, Basic Pharma Technoliges B.V.
|14.45||Regulatory aspects during (early) development of biopharmaceuticals
Jacques Havermans, Interdos Pharma B.V.
|15.10||SME pitches: Novel technologies in personalised medicine
Matisse Pharmaceuticals BV- Geleen- Peter Ekhart
Noviocell BV – Pivot Park Oss - Juliette van den Dolder
The meeting is especially of interest to companies active in biotechnology, pharmaceuticals and medical devices. You can register for the event free of charge (registration mandatory) via: www.lifeteczone.nl/nl/agenda/mei2019